Abstract
The chronic inflammatory disease atherosclerosis, is caused by the buildup of plaque within the arteries. This may result in the narrowing and stiffening of the lumen. Current studies have shifted towards innovative treatments that target specific proteins central to atherosclerosis development. The subject of focus in this article is ApoA-I, a crucial component in the mechanism of reverse cholesterol transportation. ApoA-I’s high effectiveness in interacting with ABCA1 and ABCG1 receptors on membranes facilitates the extraction of phospholipids and cholesterol from foam cells. In vivo experiments suggest that ApoA-I could serve as a novel therapeutic target for coronary atherosclerosis, but its extended effects require further investigation. The last step in the advancements of ApoA-I research would be clinical and human-based trials. As of currently, no human treatment experiments have been carried out, and the effect loss caused by a rejection reaction cannot be ruled out, and more research must be done before it is medically used.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call